- Home
- GPRO vs CHRS Comparison
GPRO vs CHRS Comparison
Compare GPRO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRO
- CHRS
- Stock Information
- Founded
- GPRO 2004
- CHRS 2010
- Country
- GPRO United States
- CHRS United States
- Employees
- GPRO N/A
- CHRS N/A
- Industry
- GPRO Industrial Machinery/Components
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GPRO Consumer Discretionary
- CHRS Health Care
- Exchange
- GPRO Nasdaq
- CHRS Nasdaq
- Market Cap
- GPRO 102.2M
- CHRS 84.2M
- IPO Year
- GPRO 2014
- CHRS 2014
- Fundamental
- Price
- GPRO $0.74
- CHRS $0.82
- Analyst Decision
- GPRO Hold
- CHRS Buy
- Analyst Count
- GPRO 1
- CHRS 3
- Target Price
- GPRO $1.50
- CHRS $4.68
- AVG Volume (30 Days)
- GPRO 5.2M
- CHRS 1.3M
- Earning Date
- GPRO 08-05-2025
- CHRS 08-07-2025
- Dividend Yield
- GPRO N/A
- CHRS N/A
- EPS Growth
- GPRO N/A
- CHRS N/A
- EPS
- GPRO N/A
- CHRS N/A
- Revenue
- GPRO $780,312,000.00
- CHRS $272,251,000.00
- Revenue This Year
- GPRO N/A
- CHRS N/A
- Revenue Next Year
- GPRO $6.79
- CHRS $106.56
- P/E Ratio
- GPRO N/A
- CHRS $1.87
- Revenue Growth
- GPRO N/A
- CHRS 19.87
- 52 Week Low
- GPRO $0.40
- CHRS $0.66
- 52 Week High
- GPRO $1.76
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- GPRO 46.62
- CHRS 53.13
- Support Level
- GPRO $0.67
- CHRS $0.72
- Resistance Level
- GPRO $0.95
- CHRS $0.77
- Average True Range (ATR)
- GPRO 0.06
- CHRS 0.04
- MACD
- GPRO -0.02
- CHRS 0.01
- Stochastic Oscillator
- GPRO 23.09
- CHRS 91.62
About GPRO GoPro Inc.
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.